New Pharmaceuticals market report from Global Markets Direct: "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014"

Boston, MA -- (ReleaseWire) -- 04/14/2014 --Global Markets Direct's, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014', provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

View Full Report Details and Table of Contents

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects

Companies Mentioned in this Report: AstraZeneca PLC, Eli Lilly and Company, Viralytics Ltd., Genentech, Inc., Bavarian Nordic A/S, Emergent BioSolutions Inc., Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals, Inc., Novartis AG, Astellas Pharma Inc., GTx, Inc., Teva Pharmaceutical Industries Limited, Progenics Pharmaceuticals, Inc., Exelixis, Inc., Onyx Pharmaceuticals, Inc., Merck KGaA, Active Biotech AB, Oncolytics Biotech Inc., Oncothyreon Inc., Medivation, Inc., Synta Pharmaceuticals Corp., Supratek Pharma Inc., CellCentric Ltd., CureVac GmbH, GenSpera, Inc., Bind Therapeutics, Inc., NewLink Genetics Corporation, Bellicum Pharmaceuticals, Inc., Bostwick Laboratories, Inc., ATLAB Pharma SAS, DexTech Medical AB, AbbVie Inc., Sotio a.s.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2013
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013
- Metastatic Colorectal Cancer - Pipeline Review, H1 2014
- Metastatic Pancreatic Cancer - Pipeline Review, H1 2014
- Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014
- Metastatic Liver Cancer - Pipeline Review, H1 2014
- Colon Cancer - Pipeline Review, H1 2014
- Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014
- Small-Cell Lung Cancer - Pipeline Review, H1 2014